Developer docs
API playgroundTry for free, no card

Search company profiles

Contraline

Full company profile

uuid0000j62

Namestring
Contraline
Legal namestring
Contraline, Inc.
Websiteurl
contraline.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Contraline is a clinical-stage biopharmaceutical company developing male contraceptive technologies. Headquartered in Charlottesville, Virginia, the company operates with 11–50 employees and is led by co-founder and CEO Kevin Eisenfrats. Contraline targets the unmet need for reversible male contraception — a category in which approximately three-quarters of couples currently rely on female-only contraceptive methods. The company is pre-revenue, and both of its investigational products have not received approval from the FDA or any other regulatory authority.

The company is developing two candidates built on distinct technical platforms. The lead hormonal candidate, NES/T Gel, is a once-daily topical gel combining segesterone acetate (Nestorone) with testosterone that suppresses sperm production while maintaining physiological testosterone levels. NES/T Gel completed a Phase 2b trial enrolling 462 couples across 17 global sites, and Phase 3 development is anticipated in 2027 — described as the first-ever Phase 3 trial of a pharmacological male contraceptive. The second candidate, ADAM, is a non-hormonal polyethylene glycol hydrogel injected into the vas deferens that blocks sperm transport via 10–20 nm pore architecture while permitting small-molecule diffusion; the hydrogel is designed to last 2+ years and liquefies at end-of-life to restore fertility. ADAM completed a Phase 1 trial in 25 participants in Australia.

Contraline's future revenue model is expected to rely on prescription pharmaceutical sales for NES/T Gel and ADAM, supplemented by licensing royalties in territories the company does not commercialize directly. The company holds exclusive worldwide rights to NES/T through a February 2026 license with the Population Council, which originally co-developed the technology with NICHD/NIH. To date, Contraline has raised approximately $92.5 million cumulatively across seed, Series A, and Series B rounds, with the most recent $92.5M Series B in June 2026 co-led by BVF Partners and RA Capital Management.

Short descriptiontext

Contraline is a clinical-stage biotechnology company developing two proprietary male contraceptive technologies: ADAM, a non-hormonal hydrogel vas-deferens implant, and NES/T Gel, a once-daily hormonal topical gel. The company targets men and couples seeking reversible contraception, with Phase 3 trials for NES/T planned for 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCharlottesville, United States
HQ citystring
Charlottesville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
male contraception, contraceptive hydrogel implant, hormonal contraceptive gel, reproductive health therapeutics, vas deferens occlusion
Industry1 code
PRIMARYHLAKAOAD
Male Reproductive & Sexual Medicine (Andrology)
Product category
Male Contraceptives
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeSubscription Recurring
Description

Contraline is a clinical-stage biopharmaceutical company developing male contraceptives. The company expects to commercialize NES/T Gel and ADAM upon regulatory approval, likely generating revenue through prescription pharmaceutical sales. NES/T Gel holds exclusive worldwide rights from Population Council.

contraline.com
2Licensing Royalties
TypeLicensing Royalties
Description

Contraline holds exclusive worldwide rights to develop and commercialize NES/T. Potential future licensing arrangements may generate royalty revenue in markets where Contraline does not commercialize directly.

contraline.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1NES/T Gel
Description

An investigational daily topical gel combining segesterone acetate (Nestorone) with testosterone for reversible male contraception.

contraline.com
+1 more record
Core offering1 text field

Contraline is a clinical-stage biopharmaceutical company developing two investigational male contraceptive products: ADAM, a non-hormonal, long-lasting polyethylene glycol hydrogel implant injected into the vas deferens to block sperm transport, and NES/T Gel, a once-daily topical gel combining segesterone acetate (Nestorone) with testosterone to suppress sperm production while maintaining normal testosterone levels. Both products are designed to be reversible and address the lack of appealing male contraceptive options.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NES/T Phase 2b: Demonstrated efficacy, tolerability, reversibility, and user acceptability in 462 couples across 17 global sites
+2 more records
Product overview1 text field

Contraline is developing a portfolio of male contraceptive products consisting of two investigational candidates: NES/T Gel and ADAM Implant. NES/T is a once-daily topical hormonal gel that suppresses sperm production through a novel combination of segesterone acetate (Nestorone) and testosterone, designed for short-term reversible contraception. ADAM is a long-lasting, non-hormonal hydrogel implant that provides contraceptive protection for up to 24 months through vas-occlusion, offering a 'set and forget' alternative. Together, these products aim to provide men with both short-acting and long-acting reversible contraceptive options, addressing the current lack of appealing male contraceptive methods.

Product and service2 records
1NES/T Gel
CategoryMale Contraceptives
Description

An investigational once-daily topical gel combining segesterone acetate (Nestorone) with testosterone, designed to suppress sperm production while maintaining physiological testosterone levels. Applied to the shoulders and upper arms, the hormonal product is reversible upon discontinuation and targets men seeking short-term reversible contraception.

2ADAM Implant
CategoryMale Contraceptives
Description

An investigational long-lasting, non-hormonal, reversible hydrogel contraceptive implant injected into the vas deferens to block sperm transport. The polyethylene glycol-based implant is effective for an estimated 2+ years before the hydrogel liquefies and restores fertility, offering men a minimally invasive outpatient procedure.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-04
Description

Contraline executed a global exclusive license agreement with Population Council for NES/T male contraception gel. The Population Council co-developed NES/T with NICHD/NIH and transfers all development and commercialization rights to Contraline for late-stage development and global regulatory approvals.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the U.S. National Institutes of Health, co-developed NES/T with Population Council and provided research support for clinical trials.

3Male Contraceptive Initiative
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Male Contraceptive Initiative provided support for NES/T development, advancing male contraceptive research.

podcast.labiotech.eu
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developing EP055, a non-hormonal male contraceptive targeting Eppin protein on sperm surface. Direct peer in non-hormonal male contraception research.

TypeDirect peer
Description

Developing Plan A, a non-hormonal vas-deferens occlusive male contraceptive using a similar approach to Contraline's ADAM implant. Most directly comparable competitor in the male contraceptive space.

TypeDirect peer
Description

Developing YCT-529, an oral non-hormonal male contraceptive pill targeting the retinoic acid receptor. Direct competitor in male contraception with a different delivery mechanism.

TypeEmerging player
Description

Early-stage company developing reversible vas-deferens occlusion technology for male contraception. Competing approach to Contraline's ADAM with similar long-acting, non-hormonal positioning.

TypeBroad incumbent
Description

Global nonprofit research organization that originally co-developed NES/T with NICHD/NIH and licensed it to Contraline. Comparable as a contraceptive R&D organization and Contraline's key licensor.

TypeBroad incumbent
Description

Global women's health company with extensive contraceptive portfolio (NuvaRing, Nexplanon, Cerazette). Likely strategic acquirer or competitor if it expands into male contraception.

TypeBroad incumbent
Description

Major pharmaceutical company with established contraceptive brands (Mirena, Yaz, Kyleena) and significant R&D resources. Potential acquirer and competitive threat in reproductive health.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company focused on women's reproductive health with multiple contraceptive and hormone therapy candidates. Comparable biotech business model in adjacent reproductive health category.

TypeEmerging player
Description

Biomedical company developing women's reproductive health products including permanent contraception (FemaSeed). Comparable as a clinical-stage reproductive health device/drug company.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing therapeutics in women's health, including HPV-related cervical pre-cancer. Comparable clinical-stage biotech model in reproductive health, though different therapeutic focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors33 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Contraline

Male Contraceptivescontraline.com

Contraline is a clinical-stage biotechnology company developing two proprietary male contraceptive technologies: ADAM, a non-hormonal hydrogel vas-deferens implant, and NES/T Gel, a once-daily hormonal topical gel. The company targets men and couples seeking reversible contraception, with Phase 3 trials for NES/T planned for 2027.

What Contraline does

Contraline is a clinical-stage biopharmaceutical company developing male contraceptive technologies. Headquartered in Charlottesville, Virginia, the company operates with 11–50 employees and is led by co-founder and CEO Kevin Eisenfrats. Contraline targets the unmet need for reversible male contraception — a category in which approximately three-quarters of couples currently rely on female-only contraceptive methods. The company is pre-revenue, and both of its investigational products have not received approval from the FDA or any other regulatory authority.

The company is developing two candidates built on distinct technical platforms. The lead hormonal candidate, NES/T Gel, is a once-daily topical gel combining segesterone acetate (Nestorone) with testosterone that suppresses sperm production while maintaining physiological testosterone levels. NES/T Gel completed a Phase 2b trial enrolling 462 couples across 17 global sites, and Phase 3 development is anticipated in 2027 — described as the first-ever Phase 3 trial of a pharmacological male contraceptive. The second candidate, ADAM, is a non-hormonal polyethylene glycol hydrogel injected into the vas deferens that blocks sperm transport via 10–20 nm pore architecture while permitting small-molecule diffusion; the hydrogel is designed to last 2+ years and liquefies at end-of-life to restore fertility. ADAM completed a Phase 1 trial in 25 participants in Australia.

Contraline's future revenue model is expected to rely on prescription pharmaceutical sales for NES/T Gel and ADAM, supplemented by licensing royalties in territories the company does not commercialize directly. The company holds exclusive worldwide rights to NES/T through a February 2026 license with the Population Council, which originally co-developed the technology with NICHD/NIH. To date, Contraline has raised approximately $92.5 million cumulatively across seed, Series A, and Series B rounds, with the most recent $92.5M Series B in June 2026 co-led by BVF Partners and RA Capital Management.

Contraline firmographics

Firmographics
Name
Contraline
Legal name
Contraline, Inc.
Website
https://contraline.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Contraline is a clinical-stage biotechnology company developing two proprietary male contraceptive technologies: ADAM, a non-hormonal hydrogel vas-deferens implant, and NES/T Gel, a once-daily hormonal topical gel. The company targets men and couples seeking reversible contraception, with Phase 3 trials for NES/T planned for 2027.
Ownership category
akta.pro rank

Contraline industry classification

Industry
Product category
Male Contraceptives
akta.pro industry
PRIMARYHLAKAOAD
Male Reproductive & Sexual Medicine (Andrology)

Keywords

  • Male contraception
  • Contraceptive hydrogel implant
  • Hormonal contraceptive gel
  • Reproductive health therapeutics
  • Vas deferens occlusion

Where Contraline is headquartered

Location

Headquarters

HQ city
Charlottesville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Contraline business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: Contraline is a clinical-stage biopharmaceutical company developing male contraceptives. The company expects to commercialize NES/T Gel and ADAM upon regulatory approval, likely generating revenue through prescription pharmaceutical sales. NES/T Gel holds exclusive worldwide rights from Population Council.
  2. Licensing Royalties: Contraline holds exclusive worldwide rights to develop and commercialize NES/T. Potential future licensing arrangements may generate royalty revenue in markets where Contraline does not commercialize directly.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Contraline product offering

Product offering

Core offering

Contraline is a clinical-stage biopharmaceutical company developing two investigational male contraceptive products: ADAM, a non-hormonal, long-lasting polyethylene glycol hydrogel implant injected into the vas deferens to block sperm transport, and NES/T Gel, a once-daily topical gel combining segesterone acetate (Nestorone) with testosterone to suppress sperm production while maintaining normal testosterone levels. Both products are designed to be reversible and address the lack of appealing male contraceptive options.

Product overview

Contraline is developing a portfolio of male contraceptive products consisting of two investigational candidates: NES/T Gel and ADAM Implant. NES/T is a once-daily topical hormonal gel that suppresses sperm production through a novel combination of segesterone acetate (Nestorone) and testosterone, designed for short-term reversible contraception. ADAM is a long-lasting, non-hormonal hydrogel implant that provides contraceptive protection for up to 24 months through vas-occlusion, offering a 'set and forget' alternative. Together, these products aim to provide men with both short-acting and long-acting reversible contraceptive options, addressing the current lack of appealing male contraceptive methods.

Differentiator

Problem solved

Functional benefit

Brands

  • NES/T Gel: An investigational daily topical gel combining segesterone acetate (Nestorone) with testosterone for reversible male contraception.
  • ADAM

Products and services

  • NES/T Gel An investigational once-daily topical gel combining segesterone acetate (Nestorone) with testosterone, designed to suppress sperm production while maintaining physiological testosterone levels. Applied to the shoulders and upper arms, the hormonal product is reversible upon discontinuation and targets men seeking short-term reversible contraception.
  • ADAM Implant An investigational long-lasting, non-hormonal, reversible hydrogel contraceptive implant injected into the vas deferens to block sperm transport. The polyethylene glycol-based implant is effective for an estimated 2+ years before the hydrogel liquefies and restores fertility, offering men a minimally invasive outpatient procedure.

Quantifiable outcome

  • NES/T Phase 2b: Demonstrated efficacy, tolerability, reversibility, and user acceptability in 462 couples across 17 global sites
  • +2 more outcomes

Companies that use Contraline

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Contraline technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Contraline partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Population CouncilcoreStrategic or Co-development Partner · 4 February 2026Contraline executed a global exclusive license agreement with Population Council for NES/T male contraception gel. The Population Council co-developed NES/T with NICHD/NIH and transfers all development and commercialization rights to Contraline for late-stage development and global regulatory approvals.
  • NICHD/NIH (National Institute of Child Health and Human Development)coreStrategic or Co-development PartnerThe Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the U.S. National Institutes of Health, co-developed NES/T with Population Council and provided research support for clinical trials.
  • Male Contraceptive InitiativeminorStrategic or Co-development PartnerMale Contraceptive Initiative provided support for NES/T development, advancing male contraceptive research.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Contraline competitors and assessment

Company assessment

Direct peers

  • Eppin Pharma: Developing EP055, a non-hormonal male contraceptive targeting Eppin protein on sperm surface. Direct peer in non-hormonal male contraception research.
  • NEXT Life Sciences: Developing Plan A, a non-hormonal vas-deferens occlusive male contraceptive using a similar approach to Contraline's ADAM implant. Most directly comparable competitor in the male contraceptive space.
  • YourChoice Therapeutics: Developing YCT-529, an oral non-hormonal male contraceptive pill targeting the retinoic acid receptor. Direct competitor in male contraception with a different delivery mechanism.

Emerging players

  • Revolution Contraceptives: Early-stage company developing reversible vas-deferens occlusion technology for male contraception. Competing approach to Contraline's ADAM with similar long-acting, non-hormonal positioning.
  • Daré Bioscience: Clinical-stage biopharmaceutical company focused on women's reproductive health with multiple contraceptive and hormone therapy candidates. Comparable biotech business model in adjacent reproductive health category.
  • Femasys: Biomedical company developing women's reproductive health products including permanent contraception (FemaSeed). Comparable as a clinical-stage reproductive health device/drug company.
  • Antiva Biosciences: Clinical-stage biopharmaceutical company developing therapeutics in women's health, including HPV-related cervical pre-cancer. Comparable clinical-stage biotech model in reproductive health, though different therapeutic focus.

Broad incumbents

  • Population Council: Global nonprofit research organization that originally co-developed NES/T with NICHD/NIH and licensed it to Contraline. Comparable as a contraceptive R&D organization and Contraline's key licensor.
  • Organon: Global women's health company with extensive contraceptive portfolio (NuvaRing, Nexplanon, Cerazette). Likely strategic acquirer or competitor if it expands into male contraception.
  • Bayer: Major pharmaceutical company with established contraceptive brands (Mirena, Yaz, Kyleena) and significant R&D resources. Potential acquirer and competitive threat in reproductive health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Contraline social profiles

Digital presence

Contraline financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Contraline leadership team

Management profile

Number of profiles

Profiles5 records

Contraline funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors33 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Contraline M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Contraline

What does Contraline do?

Contraline is a clinical-stage biopharmaceutical company developing two investigational male contraceptive products: ADAM, a non-hormonal, long-lasting polyethylene glycol hydrogel implant injected into the vas deferens to block sperm transport, and NES/T Gel, a once-daily topical gel combining segesterone acetate (Nestorone) with testosterone to suppress sperm production while maintaining normal testosterone levels. Both products are designed to be reversible and address the lack of appealing male contraceptive options.

Is Contraline a public or private company?

Contraline is a private company. It is classified as venture growth investor backed and is currently operating.

When was Contraline founded?

Contraline was founded in 2015. It employs 11 to 50 people.

Where is Contraline based?

Contraline is headquartered in Charlottesville, United States, in the North America region.

How does Contraline make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties.

Who are Contraline's main competitors?

Direct peers on record are Eppin Pharma, NEXT Life Sciences and YourChoice Therapeutics. Emerging players are Revolution Contraceptives, Daré Bioscience, Femasys and Antiva Biosciences. Broad incumbents are Population Council, Organon and Bayer.

Does Contraline have an API?

No public API is recorded for Contraline.

What industry is Contraline in?

Contraline's product category is Male Contraceptives. Its primary akta.pro industry code is HLAKAOAD, Male Reproductive & Sexual Medicine (Andrology).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Clinical Trials ArenaClinical trial success increasingly dependent on strategic collaborations and tech applicationsArena International's Outsourcing in Clinical Trials Southern California conference returns for its 14th edition in September 2026 in San Diego. The event will feature sessions on AI, tech, and innovation, with keynotes from Craig Chambliss and Robert Goldman. The conference aims to discuss collaboration, budget planning, and patient participation in clinical trials.LinkedInContralineContraline announced the closing of a $92.5 million Series B financing round co-led by BVF Partners and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other healthcare investors. The funding will support late-stage development of NES/T Gel, a daily-use reversible male contraceptive that recently completed a global Phase 2b clinical trial enrolling 462 couples, and advance the company's broader pipeline including ADAM, a long-lasting non-hormonal male contraceptive. The company anticipates initiating a Phase 3 trial in 2027, which would be the first Phase 3 trial for a pharmacological male contraceptive in history.FundraiseinsiderContraline Raises $92.5M Series B for Male ContraceptiveContraline, a clinical-stage biotech company based in Charlottesville, Virginia, closed a $92.5 million Series B financing round co-led by BVF Partners and RA Capital Management, with participation from GV, Lumira Ventures, Invus, and other investors. The company is developing NES/T, a once-daily topical gel combining segesterone acetate with testosterone as a reversible male contraceptive that recently completed a global Phase IIb clinical trial with 462 couples and is positioned to potentially become the first approved pharmacologic contraceptive for men. The financing will support Phase 3 development starting in 2027, while the company also advances ADAM, another male contraceptive candidate in clinical development.MedCity NewsContraline Secures $92.5M to Push Its Male Birth Control Candidates ForwardContraline closed a $92.5 million Series B round led by BVF Partners and RA Capital Management, bringing total funding to $127 million. The company will use most of the funds for NES/T's Phase 3 trial, with ADAM entering Phase 2 next year. CEO Kevin Eisenfrats expects to work quickly to get both products on the market.GeneOnline NewsContraline Raises $92.5 Million in Series B Funding for ADAM Male Contraceptive TrialsContraline secured $92.5 million in Series B funding to advance its ADAM reversible male contraceptive device into late-stage clinical trials. ADAM is a hydrogel implant that blocks sperm transport in the vas deferens, representing a non-hormonal alternative to existing contraceptive methods. The company plans to use the capital to scale operations, complete Phase III clinical evaluations, and prepare for potential commercialization pending regulatory approval.Pharmaceutical TechnologyContraline secures $92.5m to push male contraceptive into late-stage trialsContraline has closed a $92.5 million Series B financing round, co-led by RA Capital Management and BVF Partners with participation from Google Ventures and Lumira Ventures, to fund late-stage Phase III trials of its NES/T Gel — a topical, reversible male contraceptive. The funding positions Contraline to potentially become the first company to commercialize a pharmacological male contraceptive, with Phase III trials planned for 2027 after positive Phase IIb data across 462 couples. The article also notes the broader US reproductive health policy context, including tightening abortion laws and recent Supreme Court rulings on the abortion pill mifepristone.HomepageContraline Raises $92.5M Series B to Advance Male Contraceptive Gel Into Phase 3Contraline, a clinical-stage biopharmaceutical company, has closed a $92.5 million Series B funding round co-led by BVF Partners and RA Capital Management, with participation from GV, Lumira Ventures, and Invus, to advance NES/T Gel into Phase 3 clinical development anticipated in 2027. NES/T is an investigational hormonal, reversible male contraceptive topical gel combining segesterone acetate with testosterone, which recently completed a global Phase 2b trial enrolling 462 couples. If approved, NES/T would become the first pharmacologic contraceptive for men, a category that has remained empty despite decades of research, with survey data suggesting more than 40 million men in the U.S. would consider using a novel male contraceptive.Pulse 2.0Contraline Raises $92.5 Million Series B To Advance Male Contraceptive NES/T Gel Into Late-Stage DevelopmentContraline, a clinical-stage biopharmaceutical company developing male contraceptives, closed a $92.5 million Series B financing round co-led by BVF Partners L.P. and RA Capital Management, with participation from GV, Lumira Ventures, Invus, and other investors. The funding will support late-stage development of NES/T Gel, an investigational hormonal, reversible male contraceptive that completed a global Phase 2b trial with 462 couples and is expected to begin Phase 3 in 2027. Survey data suggest more than 40 million men in the United States would consider using a novel male contraceptive, highlighting the potential market opportunity for expanded male reproductive health options.YahooContraline secures $92.5m to push male contraceptive into late-stage trialsContraline has closed a $92.5 million Series B financing round co-led by RA Capital Management and BVF Partners, with participation from Google Ventures and others, to advance its NES/T Gel male contraceptive through late-stage development, with Phase III trials planned for 2027. The topical contraceptive, which combines Nestorone with testosterone to suppress sperm production while maintaining testosterone levels, has already demonstrated efficacy, tolerability, and reversibility in a Phase IIb trial of 462 couples, positioning it as a potential first approved pharmacological male contraceptive. The funding comes amid shifting reproductive health laws in the US, including FDA approval of generic mifepristone and ongoing legal challenges around abortion access.VabioContraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage DevelopmentContraline, Inc. announced the closing of a $92.5 million Series B financing round co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other investors. The proceeds will support late-stage development of NES/T Gel, an investigational hormonal, reversible male contraceptive that completed a global Phase 2b clinical trial with 462 couples showing encouraging efficacy and tolerability results. The company plans to initiate Phase 3 clinical development in 2027, positioning NES/T as a potential first approved pharmacologic contraceptive for men.